SMMT Summit Therapeutics Inc. - Common Stock

NAS · US · Healthcare · Biotechnology · smmttx.com

16.75USD+0.39%Mkt Cap: 13.37B $P/E: —4d ago

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate …

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

BBIO

BridgeBio Pharma, Inc. - Common Stock

$13.15BUSD

Key Statistics

Company

Market Cap13.37B USD

Enterprise Value12.70B USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-1.08B USD

Revenue/Share—

Last Price16.75 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees265

CountryUS

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-14.68

PEG—

EV/EBITDA-14.52

EV/Revenue—

P/S—

P/B21.10

EPS (TTM)-1.11

EPS (Forward)-1.14

52W Range

12.0727% of range29.23

52W High29.23 USD

52W Low12.07 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-163.86%

ROA-143.72%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-322.93M USD

CapEx (TTM)657.00K USD

FCF Margin—

FCF Yield-1.05%

Net Debt-670.29M USD

Net Debt/EBITDA0.77

Balance Sheet

Debt/Equity0.03

Current Ratio6.96

Quick Ratio6.67

Book Value/Sh0.79 USD

Cash/Share0.87 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.8 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)29.68 USD

Upside (mean)+77.1%

Target Range11.52 USD – 42.98 USD

11.52+77.1% to mean42.98

# Analysts13

Ownership

Shares Out.797.75M

Float152.28M

Insiders80.89%

Institutions17.58%

Short Interest

Short Ratio6.4d

Short % Float26.26%

Short % Out.5.15%

Shares Short41.08M

Short (prev mo.)37.43M

Technical

SMA 5015.03 (+11.5%)

SMA 20016.36 (+2.4%)

Beta-1.24

S&P 52W Chg14.58%

Avg Vol (30d)7.26M

Avg Vol (10d)8.28M

Technical Indicators

RSI (14)55.1

MACD0.4465

MACD Signal0.5645

MACD Hist.-0.1180

BB Upper18.85 USD

BB Middle16.72 USD

BB Lower14.58 USD

BB Width25.54%

ATR (14)1.138 USD

Vol Ratio (20d)0.69x